Steven M. Larson, MD, FACNM, FACR receives 2018 ACNM Gold Medal Award
Dr. Larson is one of the pioneers of targeted radionuclide therapy and PET (including immunoPET). Dr. Larson is also responsible for developing and directing successful Nuclear Medicine and PET programs at the Portland Veteran Administration Hospitals, the University of Oregon, the Seattle Veterans Administration Hospital, the Clinical Center of National Institutes of Health (NIH), and finally Memorial Sloan Kettering Cancer Center (MSKCC). Through these transitions, Dr. Larson has maintained a productive and well-funded clinical and pre-clinical program, most recently concentrating on multi-step targeting. At his core, he is a dual-boarded physician-scientist in Nuclear Medicine and Internal Medicine with an expertise in oncology and subspecialty interest in cancer immunology and management of thyroid cancer.
He has received numerous scientific and clinical awards from our community, including the Hevesy Award, Cassen and the inaugural Hertz Prize of the SNMMI. In addition, he has received multiple accolades from other medical societies including being inducted into the Institute of Medicine. He has served as a tenured member of several National Institute of Health (NIH) review committees, the Department of Energy (DOE) Office of Science Advisory Committee, and the American Board of Nuclear Medicine and as Chair of the Radiopharmaceutical Advisory Committee of the Food and Drug Administration (FDA), and Chair of the Molecular Imaging Committee of Radiological Society of North America (RSNA). Dr. Larson is Chair of the Clinical Imaging Steering Committee of the National Cancer Institute and of its study section of NIH. Dr. Larson has himself been the Principal Investigator or Co-Principal Investigator on numerous NIH grants, with millions of dollars in research funding over the last several decades. He has > 500 peer-reviewed publications and seven patents to his credit.